FIRST AIRED: October 31, 2017

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



>> The wide ranging investigation into sky high prices for generic drugs in the US, exploding in scope. US state attorneys general from 45 states and the District of Columbia, moving Tuesday to expand their lawsuit. Alleging that 18 companies conspired to jack up the prices of 15 different generic drugs.
But that's not all. The lawsuit also roping in two individual executives, including the CEO of Emcure Pharmaceuticals and the president of Mylan Pharmaceuticals, which manufactures EpiPen. The subject of nationwide outrage last year after Mylan raised the price of EpiPens by roughly 500% over a seven-year period. The company in a statement saying it stands behind its president, and vowed to defend itself vigorously.
Shares of Mylan fell nearly 8% after the news. The stocks of several other pharmaceutical companies in the expanded complained plunging as well, including Lannett and Endo International. The original complaint, filed at the end of last year, targeted just six companies and only two generic medicines. The amended complaint now includes a blood pressure medicine, an antianxiety drug, and more commonly used treatments for diabetes.